FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

While this hype may be warranted in some respects—a 60-year old legal provision has now been amended to acknowledge that the science of drug development is advancing—the change is mostly symbolic and is likely to take many years before we see it have a measurable impact. 42 U.S.C. § 262(k)(2)(A)(i)(I).

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays Clinical Trials 64

Predictive Oncology

AUGUST 8, 2024

Most drug failures occur in Phase II and Phase III clinical trials when drugs move from immortalized cell lines and animal testing to human patients. By combining these two assets, this offering represents an opportunity to de-risk drug discovery and accelerate pipeline development.

Drug Development 52

Drug Development Clinical Trials Animal Testing Drugs 52

FDA Law Blog: Drug Discovery

SEPTEMBER 27, 2023

The issues appropriate for an INTERACT meeting typically relate to IND requirements, such as questions about IND-enabling studies, complex manufacturing technologies or processes, development of innovative devices used with a drug or biologic, or the use of New Approach Methodologies (methods to be used in place of traditional animal testing).

FDA 64

FDA Packaging Animal Testing Production 64

The Premier Consulting Blog

APRIL 25, 2023

As a result, the FDA is now required to consider alternatives to animal testing, such as in vitro , in silico , and in chemico tests and models. In this blog post, we examine several alternative approaches to animal testing and how the FDA handles the application of these methods in specific scenarios.

FDA 52

FDA Animal Testing Pharmacokinetics Pharmaceuticals 52

Codon

JUNE 2, 2024

” It’s an uncharitable take, but when drugs fail as often as they do despite animal testing, it’s not hard to see the JAX mice as a metaphor for a biomedical enterprise cloistered away from the real world. In his spare time he enjoys blogging about biotechnology. Cite this essay: Alex Telford.

Laboratories 128

Laboratories Research Disease Science 128

FDA Law Blog: Drug Discovery

DECEMBER 6, 2024

Instead, this guidance highlights questions about species, animal model, and product selection for nonclinical programs as well as several aimed at helping to understand the purpose and importance of POC, toxicity, and biodistribution studies. Stay tuned for the next iteration of the Cliffs Notes to the Cliffs Notes.

Therapies 59

Therapies FDA Production Disease 59